Experienced in Cavernous Lymphangioma

Kuan-yu H. Chen

No.1 Changde St, 100, 
Zhongzheng Dist, TPQ, TW 
Experienced in Cavernous Lymphangioma
No.1 Changde St, 100, 
Zhongzheng Dist, TPQ, TW 
OverviewLocationsClinical Research

Overview

Kuan-yu Chen practices in Zhongzheng Dist, Taiwan. Chen is rated as an Experienced expert by MediFind in the treatment of Cavernous Lymphangioma. Their top areas of expertise are Lung Adenocarcinoma, Lung Cancer, EGFR Positive Lung Cancer, and Abdominal Cystic Lymphangioma.

Their clinical research consists of co-authoring 261 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Cavernous Lymphangioma.

Locations

No.1 Changde St, 100, Zhongzheng Dist, TPQ, Taiwan
Other Locations
100 Tzyou Road, 807, Kaohsiung, KHQ, Taiwan
No. 7, Chung Shan South Road, 100, TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy
A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy
Enrollment Status: Completed
Publish Date: July 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase IB/II, Open Label, Multicenter Study of Selumetinib Administered Orally in Combination With Gefitinib in Patients With EGFR-mutated Non-small Cell Lung Cancer Who Have Developed Acquired Resistance of EGFR Inhibitor Treatment
A Phase IB/II, Open Label, Multicenter Study of Selumetinib Administered Orally in Combination With Gefitinib in Patients With EGFR-mutated Non-small Cell Lung Cancer Who Have Developed Acquired Resistance of EGFR Inhibitor Treatment
Enrollment Status: Completed
Publish Date: July 10, 2018
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

261 Total Publications

Pitch Dynamics and Aerodynamic Interactions in Damselfly-Inspired Micro Air Vehicles: The Role of the Position of the Center-of-Mass.
Pitch Dynamics and Aerodynamic Interactions in Damselfly-Inspired Micro Air Vehicles: The Role of the Position of the Center-of-Mass.
Journal: Bioinspiration & biomimetics
Published: July 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chen's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile